Summary of Use during Lactation

No information is available on the clinical use of apremilast during breastfeeding. Although it is not contraindicated, international guidelines recommend avoiding apremilast during breastfeeding.[1-3] An alternate drug may be preferred, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.

Rademaker M, Agnew K, Andrews M, et al. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. Australas J Dermatol. 2018;59:86–100. [PubMed: 28543445]

2.

Puchner A, Grochenig HP, Sautner J, et al. Immunosuppressives and biologics during pregnancy and lactation: A consensus report issued by the Austrian Societies of Gastroenterology and Hepatology and Rheumatology and Rehabilitation. Wien Klin Wochenschr. 2019;131:29–44. [PMC free article: PMC6342891] [PubMed: 30643992]

3.

Belinchón I, Velasco M, Ara-Martín M, et al. Management of psoriasis during preconception, pregnancy, postpartum, and breastfeeding: A consensus statement. Actas Dermosifiliogr. 2021;112:225–41. (Engl Ed) [PubMed: 33065101]

Substance Name

Apremilast

CAS Registry Number

608141-41-9

Drug Class

Breastfeeding

Lactation

Analgesics

Antirheumatic Agents

Enzyme Inhibitors

Phosphodiesterase Inhibitors